



ALK  
Investor Relations Department  
BÃge Alle 6-8  
Horsholm DK-2970  
Denmark

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### OMX: ALKB

Last Trade:	982.50
Trade Time:	12:31 PM ET Jun 27, 2017
Change:	-5.50 <span style="color: red;">↓</span> (-0.557%)
Day Range	981.50 - 988.00
52-Week Range	839.00 - 1224.00
Volume	548,500

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

ALK is the world leader in allergy vaccination (immunotherapy). It is the goal of ALK to increase the awareness of the company and its activities through a structured, ongoing, timely and balanced dialogue with investors, shareholders and other stakeholders. It is also a company goal to secure the liquidity of the company's shares and to generate reasonable, long-term returns to shareholders through share price increases and dividends.... [\(more\)](#)

## Company releases [\[ View all \]](#)

*Jun 1, 2017*  
[Indberetning af ledelsens transaktioner med ALK-Abell A/S' B-aktier og tilknyttede vrdipapirer](#)

*Jun 1, 2017*  
[Report on transactions with ALK-Abell A/S B-shares and associated securities by managerial staff](#)

*May 9, 2017*  
[Three-month interim report \(Q1\) 2017](#)

*May 4, 2017*  
[ALK's HDM SLIT-tablet, ACARIZAX, approved in Canada](#)

*May 3, 2017*  
[Release date of three-month interim report \(Q1\) 2017 and audio cast](#)

## Upcoming Events [\[ View all \]](#)

*Aug 16, 2017*  
[Six-month interim report \(Q2\) 2017](#)

*Sep 8, 2017*  
[Goldman Sachs Annual Biotech Symposium, London](#)